Utilisation and off-label prescriptions of respiratory drugs in children

12Citations
Citations of this article
40Readers
Mendeley users who have this article in their library.

Abstract

Respiratory drugs are widely used in children to treat labeled and non-labeled indications but only some data are available quantifying comprehensively off-label usage. Thus, we aim to analyse drug utilisation and off-label prescribing of respiratory drugs focusing on age- and indication-related off-label use. Patients aged ≤18 years documented in the Bavarian Association of Statutory Health Insurance Physicians database (approx. 2 million children) between 2004 and 2008 were included in our study. Annual period prevalence rates (PPRs) per 10,000 children and the proportion of age- and indication-related off-label prescriptions were calculated and stratified by age and gender. Within the study period, highest PPRs were found for the fixed combination of clenbuterol/ambroxol (between 374-575 per 10,000 children) and the inhaled short acting beta-2-agonist salbutamol (between 378-527 per 10,000 children). Highest relative PPR increase was found for oral salbutamol (approx. 39-fold) whereas the most distinct decrease was found for oral long-acting beta-2-agonist clenbuterol (-97%). Compound classes most frequently involved in off-label prescribing were inhaled bronchodilative compounds (91,402; 37.3%) and oral beta-2-agonists (26,850; 22.5%). The highest absolute number of off-label prescriptions were found for inhaled salbutamol (n = 67,084; 42.0%) and oral clenbuterol/ambroxol (fixed combination, n = 18,897; 20.7%). Off-label prescribing due to indication was of much greater relevance than age-related off-label use. Most frequently, bronchodilative compounds were used off-label to treat respiratory tract infections. Highest off-label prescription rates were found in the youngest patients without relevant gender-related differences. Off-label prescribing of respiratory drugs is common especially in young children. Bronchodilative drugs were most frequently used off-label for treating acute bronchitis or upper respiratory tract infections underlining the essential need for a more rational prescribing in this area. © 2014 Schmiedl et al.

References Powered by Scopus

Diagnosis and management of bronchiolitis

940Citations
N/AReaders
Get full text

The impact of unlicensed and off-label drug use on adverse drug reactions in paediatric patients

147Citations
N/AReaders
Get full text

Bronchiolitis management before and after the AAP guidelines

135Citations
N/AReaders
Get full text

Cited by Powered by Scopus

The IMI PROTECT project: Purpose, organizational structure, and procedures

20Citations
N/AReaders
Get full text

Tiotropium Respimat<sup>®</sup> vs. HandiHaler<sup>®</sup>: Real-life usage and TIOSPIR trial generalizability

12Citations
N/AReaders
Get full text

Time trends of period prevalence rates of patients with inhaled long-acting beta-2-agonists-containing prescriptions: A European comparative database study

10Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Schmiedl, S., Fischer, R., Ibáñez, L., Fortuny, J., Klungel, O. H., Reynolds, R., … Rottenkolber, M. (2014). Utilisation and off-label prescriptions of respiratory drugs in children. PLoS ONE, 9(9). https://doi.org/10.1371/journal.pone.0105110

Readers over time

‘14‘15‘16‘17‘18‘19‘20‘21‘22‘23‘24036912

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 14

67%

Professor / Associate Prof. 4

19%

Researcher 3

14%

Readers' Discipline

Tooltip

Medicine and Dentistry 10

53%

Pharmacology, Toxicology and Pharmaceut... 7

37%

Materials Science 1

5%

Chemistry 1

5%

Save time finding and organizing research with Mendeley

Sign up for free
0